Carisma Therapeutics Inc. CARM
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $1.5M
- P/E
- 0.0×
Follow CARM
Growth Flags
show if company had growth for consecutive years
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
8,783.88% | 394.03% | 216.35% | (134.11%) | |
| (100.78%) | (113.13%) | (153.46%) | 33.09% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(497.55%) | (1,447.53%) | 1,060.73% | (853.72%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(1.45) | (1.13) | (0.88) | (0.52) | |
Free Cash Flow |
(60.04) | (47.14) | (36.66) | (21.73) | |
Capital Expenditures |
(0.12) | 0.42 | 0.69 | 0.69 | |
Piotroski F-Score |
4.00 | 3.00 | — | 4.00 | |
| Other line items | |||||
Cash ROIC |
600.37% | 164.44% | 84.86% | (1,173.56%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
303.96% | 257.30% | 0.00% | 48.83% | |
Selling, General and Administrative Expense of Revenue |
112.76% | 103.19% | 0.00% | 25.76% | |
Share Based Compensation of Revenue |
18.59% | 15.53% | 0.00% | 3.95% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.99 | 0.94 | 0.76 | (2.79) | |
Depreciation/Fixed assets |
0.76 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.04) | 0.18 | 0.33 | 0.52 | |
Revenue per Share |
0.47 | 0.48 | 0.00 | 1.34 | |
Operating CF per Share |
(1.45) | (1.14) | (0.89) | (0.54) | |
Capex per Share |
0.00 | 0.01 | 0.02 | 0.02 | |
Capex to Sales |
0.01 | (0.02) | 0.00 | (0.01) | |
Net Profit Margin |
(308.05%) | (254.28%) | 0.00% | 14.36% |
Columns are period end dates